Terms: = Brain cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
14 results:
1. Society for Immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract] [Full Text] [Related]
2. NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C; Kilian M; Chih YC; Kourtesakis A; Hoffmann DC; Boschert T; Koopmann P; Sanghvi K; De Roia A; Jung S; Jähne K; Day B; Shultz LD; Ratliff M; Harbottle R; Green EW; Will R; Wick W; Platten M; Bunse L
Neuro Oncol; 2024 Feb; 26(2):266-278. PubMed ID: 37715782
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.
Takei J; Kamata Y; Tanaka T; Fukasawa N; Gomisawa K; Satake M; Mori R; Yamamoto Y; Suzuki T; Oda A; Murahashi M; Fukuda T; Shimoda M; Murayama Y; Akasaki Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3175-3189. PubMed ID: 37382632
[TBL] [Abstract] [Full Text] [Related]
4. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract] [Full Text] [Related]
5. Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma.
Lorenzo-Herrero S; Sordo-Bahamonde C; Martínez-Pérez A; Corte-Torres MD; Fernández-Vega I; Solís-Hernández MP; González S
Cancer Sci; 2023 Jan; 114(1):48-62. PubMed ID: 36082628
[TBL] [Abstract] [Full Text] [Related]
6. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma.
Herremans KM; Szymkiewicz DD; Riner AN; Bohan RP; Tushoski GW; Davidson AM; Lou X; Leong MC; Dean BD; Gerber M; Underwood PW; Han S; Hughes SJ
Neoplasia; 2022 Jun; 28():100789. PubMed ID: 35395492
[TBL] [Abstract] [Full Text] [Related]
7. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.
Yang Y; Kim E; Kim S
Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815
[TBL] [Abstract] [Full Text] [Related]
8. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Characteristics and Postoperative Recovery of Hypopituitarism in Patients with Nonfunctional Pituitary Adenoma.
Zhang R; Wang Z; Gao L; Guo X; Feng C; Deng K; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
World Neurosurg; 2019 Jun; 126():e1183-e1189. PubMed ID: 30880207
[TBL] [Abstract] [Full Text] [Related]
10. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract] [Full Text] [Related]
11. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
[TBL] [Abstract] [Full Text] [Related]
12. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract] [Full Text] [Related]
13. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract] [Full Text] [Related]
14. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification.
Read SB; Kulprathipanja NV; Gomez GG; Paul DB; Winston KR; Robbins JM; Kruse CA
J Interferon Cytokine Res; 2003 Jul; 23(7):379-93. PubMed ID: 14511464
[TBL] [Abstract] [Full Text] [Related]
